IRVINE, Calif., Oct. 19, 2023 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) today announced the company's EVOQUE tricuspid valve replacement system received CE Mark for the transcatheter ...

Please provide your email address to receive an email when new articles are posted on . A tricuspid transcatheter edge-to-edge repair system improved tricuspid regurgitation (TR) grade for adults with ...

SAN FRANCISCO, Oct. 26, 2023 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) announced one-year results from CLASP IID, the first randomized controlled trial that directly compares two ...

Edwards Lifesciences has claimed the FDA’s first approval of a transcatheter replacement implant for a leaky tricuspid heart valve, three months after garnering a green light in Europe. The Evoque, ...

Edwards Lifesciences has secured European approval for its transcatheter tricuspid valve replacement system, which the company described as the first minimally invasive therapy of its kind to receive ...

Severe tricuspid regurgitation is a debilitating condition that is associated with substantial morbidity and often with poor quality of life. Decreasing tricuspid regurgitation may reduce symptoms and ...

Edwards Lifesciences Corp.’s catheter-based heart valve clips infringe a patent for a prosthetic support used to repair leaky ...

San Francisco — In the first randomized controlled trial using the TriClip Transcatheter Tricuspid Valve Repair system (Abbott) for transcatheter edge-to-edge repair (TEER) of the tricuspid valve in ...